home / stock / nuvl / nuvl quote
Last: | $70.88 |
---|---|
Change Percent: | -1.56% |
Open: | $73.77 |
Close: | $70.88 |
High: | $73.77 |
Low: | $70.6 |
Volume: | 348,595 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$70.88 | $73.77 | $70.88 | $73.77 | $70.6 | 348,595 | 05-17-2024 |
$72.64 | $71.8 | $72.64 | $74.5 | $71.505 | 355,080 | 05-16-2024 |
$71.68 | $69.01 | $71.68 | $72.115 | $68.95 | 467,167 | 05-15-2024 |
$68.02 | $67.03 | $68.02 | $68.56 | $66.605 | 332,517 | 05-14-2024 |
$66.08 | $66.38 | $66.08 | $67.09 | $64.67 | 348,809 | 05-13-2024 |
$65.48 | $66.7 | $65.48 | $67.8 | $64.18 | 445,545 | 05-10-2024 |
$67.52 | $66.61 | $67.52 | $67.97 | $66.6 | 325,668 | 05-09-2024 |
$67.54 | $68.12 | $67.54 | $68.65 | $66.46 | 402,741 | 05-08-2024 |
$68.64 | $69.12 | $68.64 | $70.275 | $68.31 | 367,476 | 05-07-2024 |
$69.25 | $69.99 | $69.25 | $70.69 | $68.79 | 278,450 | 05-06-2024 |
$70.35 | $73.48 | $70.35 | $74.79 | $70.125 | 346,463 | 05-03-2024 |
$72.49 | $71.52 | $72.49 | $73.29 | $70.96 | 325,740 | 05-02-2024 |
$70.65 | $69.06 | $70.65 | $72.19 | $68.07 | 532,244 | 05-01-2024 |
$68.88 | $67.25 | $68.88 | $69.64 | $67.2 | 477,196 | 04-30-2024 |
$67.95 | $67.14 | $67.95 | $68.7899 | $66.44 | 370,026 | 04-29-2024 |
$66.86 | $66.23 | $66.86 | $66.895 | $65.08 | 230,262 | 04-26-2024 |
$66.07 | $65.66 | $66.07 | $66.53 | $64.44 | 287,774 | 04-25-2024 |
$67.2 | $67.58 | $67.2 | $68.72 | $67.14 | 443,844 | 04-24-2024 |
$67.6 | $65.37 | $67.6 | $68.29 | $64.77 | 485,429 | 04-23-2024 |
$64.49 | $63 | $64.49 | $64.96 | $62.2335 | 454,885 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Nuvalent Inc. Company Name:
NUVL Stock Symbol:
NASDAQ Market:
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 PR Newswire CAMBRIDGE, Mass. , May 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therap...
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results PR Newswire Updates from the ongoing Phase 1/2 ARROS-1 and ALKOVE-1 clinical trials expected at a medical meeting in the second half of 2024 S...
2024-04-13 13:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...